A precisely positioned MED12 activation helix stimulates CDK8 kinase activity

Area of Science:

• Molecular Biology
• Biochemistry
• Cancer Biology

Background:

• The Mediator kinase module, particularly cyclin-dependent kinase 8 (CDK8), plays a crucial role in eukaryotic transcription.
• CDK8 deregulation is implicated in various cancers, highlighting its significance in disease pathogenesis.
• Understanding CDK8 regulation by its subunits, like MED12, is essential for developing targeted therapies.

Purpose of the Study:

• To elucidate the binding interaction between MED12's N-terminal segment and the CDK8/Cyclin C complex.
• To gain mechanistic insights into how MED12 activates CDK8.
• To investigate the functional consequences of MED12 mutations in cancer and their impact on kinase inhibition.

Main Methods:

• Integration of in vitro biochemistry, cross-linking coupled to mass spectrometry (XL-MS), and in vivo studies.
• Analysis of MED12 N-terminal segment binding to CDK8/Cyclin C.
• Functional assays using kinase inhibitors and transcriptome-wide gene expression analysis.

Main Results:

• MED12's N-terminal portion wraps around CDK8, positioning an activation helix crucial for CDK8 activity.
• Cancer-associated MED12 mutations affect activation helix positioning but not MED12-CDK8 binding affinity.
• MED12 binding remodels the CDK8 active site, preventing inhibition by type II kinase inhibitors and correlating with cancer gene deregulation.

Conclusions:

• A revised model for CDK8 regulation by MED12 is proposed, emphasizing the structural role of MED12 in kinase activation.
• MED12 mutations in cancer may alter CDK8 activity through altered helix positioning, impacting gene expression.
• The findings provide a basis for developing targeted small molecules against MED12-bound CDK8 complexes.